CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04519151
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:07.594713+00:00
Published At: 2023-06-08T00:00:00+00:00
Record Updated At: 2023-06-08
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ovarian Neoplasms", "Carcinoma, Ovarian Epithelial", "Neoplasm of Stomach", "Ovarian Diseases", "Genital Neoplasms, Female", "Ovarian Epithelial Tumor", "Urogenital Neoplasms", "Neoplasms, Glandular and Epithelial"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-06-08"
protocolSection.identificationModule.nctId: "NCT04519151"
protocolSection.identificationModule.officialTitle: "A Phase II, Open Lable, Single Arm, Trial to Determine Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab for Platinum- Sensitive Recurrent Ovarian Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.